// App-Quantinova.ai

P778 : Real-world drug treatment costs for ulcerative colitis and Crohn’s disease patients treated with vedolizumab vs. anti-TNFα: Results from a German retrospective chart review study

Researchers

Presenter

  • S Campbell-Hill

Principal Investigators

  • D Stein

  • M Soni

  • C Coombs

  • B Ratsch

  • J M Khalid

  • K Minda

Medical Centers

  • Takeda Development Centre Europe Ltd., Evidence and Value Generation, London, UK

  • Evidera, London, UK

  • Evidera, Bethesda, MD

  • Takeda Pharma Vertrieb GmbH & Co. KG, Market Access and Public Affairs, Berlin, Germany

  • Takeda Pharmaceutical International AG, Zürich, Switzerland

Locations

  • United Kingdom

  • United States

  • Germany

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Entyvio

  • Adalimumab

  • Infliximab

  • golimumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved